913625-37-3

Usage

Uses

Used in Organic Synthesis:
(S)-6-benzyloxycarbonylamino-4-(tert-butoxycarbonyl)-4-azaheptan-1-ol is used as an intermediate in organic synthesis for its unique molecular structure and stereochemistry, which can be utilized to create a variety of complex organic compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (S)-6-benzyloxycarbonylamino-4-(tert-butoxycarbonyl)-4-azaheptan-1-ol is used as a potential building block for the development of new drugs. Its specific stereochemistry and functional groups may contribute to the design of novel therapeutic agents.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 156-87-6 propan-1-ol-3-amine 
• 83197-70-0 (S)-2-(benzyloxycarbonylamino)propyl methanesulfonate 
• 6429-44-3 (S)-(-)-N-(benzyloxycarbonyl)alaninol 
• 501-53-1 benzyl chloroformate 
• 913625-36-2 2-(S)-2-(benzyloxycarbonyl)amino-N-(3-hydroxypropyl)propylamine 

Downstream Products

• 1360538-90-4 (S)-6-benzyloxycarbonylamino-4-(tert-butoxycarbonyl)-4-azaheptyl methanesulfonate 
• 223645-67-8 ripasudil 
• 194032-32-1 tert-butyl (S)-3-methyl-1,4-diazepane-1-carboxylate 
• 1360538-91-5 (S)-1-benzyl 4-tert-butyl 2-methyl-1,4-diazepane-1,4-dicarboxylate 
• 1011466-09-3 2-(S)-2-(benzyloxycarbonyl)amino-N-(tert-butoxycarbonyl)-N-(3-tert-butyldimethylsilyloxypropyl)propylamine 

Relevant academic research and scientific papers

IOP-lowering effect of isoquinoline-5-sulfonamide compounds in ocular normotensive monkeys

Rho-associated coiled coil-formed protein kinase (ROCK) inhibitors are under development as a new class of antiglaucoma agents. Based on the potent ROCK inhibitor H-1152, previously developed by us, we explored the possibility of related compounds as anti

NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF

The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (I) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (I) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (III) or a salt thereof with a compound represented by formula (II) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base.

Therapeutic agent for treating glaucoma

The present invention provides compounds useful as therapeutic agent for treating glaucoma and methods for treating glaucoma. That is, a therapeutic agent for treating glaucoma containing, as an active ingredient, a compound represented by formula (1) bel

4-haloisoquinoline derivative and drug containing the same

The present invention relates to compounds which have a potent Rho-kinase inhibitory action and which are useful as therapeutic agents for treating diseases, such as hypertension, pulmonary hypertension, cerebral vasospasm, angina pectoris, cardiac failur